Latest News on MD

Financial News Based On Company


Advertisement
Advertisement

Pediatrix Medical Group downgraded by Mizuho with a new price target

https://www.quantisnow.com/insight/pediatrix-medical-group-downgraded-by-mizuho-with-a-new-price-6785186
Mizuho has downgraded Pediatrix Medical Group (MD) from Neutral to Underperform, setting a new price target of $28.00. This follows previous analyst actions, including a Jefferies downgrade in August, and historical data shows varying stock performance after past headlines. The article also provides context on analyst downgrades and tools for further research into MD.

Pediatrix Medical Group (MD) Stock Still Looks Like A Bargain Despite Its 227% Run

https://sg.finance.yahoo.com/news/pediatrix-medical-group-md-stock-120855581.html
Pediatrix Medical Group (MD) has seen a significant share price increase of 226.7% over the past three years, prompting investors to scrutinize its valuation against its earnings. Despite recent earnings outperformance, the company faces margin pressure and softer operating cash flow, leading to a P/E ratio of 16.1x, which is a discount to the broader Healthcare sector and its peers. Analysts' consensus suggests the stock is currently 11% overvalued, citing portfolio restructuring and rising costs as threats to revenue stability and margin growth.

Mizuho downgrades Pediatrix Medical Group to Underperform from Neutral, keeps price target at $28

https://www.tradingview.com/news/tradingview:98d283d8442bb:0-mizuho-downgrades-pediatrix-medical-group-to-underperform-from-neutral-keeps-price-target-at-28/
Mizuho has downgraded Pediatrix Medical Group (MD) to Underperform from Neutral, while maintaining its price target at $28. This price target suggests an 11.4% downside from the stock's closing price of $31.62 on November 10. Investors can find more detailed price target data and analyst recommendations for Pediatrix Medical Group on TradingView's Forecasts tab and News Flow.

How Investors May Respond To Pediatrix Medical Group Stock As Revenue Rises And Profit Falls

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/how-investors-may-respond-to-pediatrix-medical-group-stock-a
Pediatrix Medical Group (NYSE:MD) reported increased third-quarter 2026 sales but a decline in net income, suggesting cost or reimbursement pressures are impacting profitability despite resilient demand. Analysts are now focusing on management's ability to control expenses and maintain strong hospital relationships amidst ongoing salary pressures and regulatory changes. The current earnings are US$150.1 million, with forecasts projecting revenue growth to US$2.2 billion and earnings to US$162.5 million by 2029, though fair value estimates suggest a potential downside.

Pediatrix Medical Group (MD) Wins An Analyst Upgrade, Is The Stock Now 10% Overvalued?

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/pediatrix-medical-group-md-wins-an-analyst-upgrade-is-the-st
Pediatrix Medical Group (MD) recently received an analyst upgrade, yet its stock is considered about 10% overvalued at its current price of $31.29 compared to a fair value of $28.50. Despite a strong 30-day share price return of 17.46% and a 46.97% year-to-date gain, concerns exist regarding declining consolidated revenue due to portfolio restructuring and potential pressure on margins from rising salary costs. While the current P/E ratio of 15.9x is below industry averages, the market appears to be pricing in more risk than benchmarks imply.
Advertisement

Pediatrix Medical Group, Inc. (MD) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/MD/seasonality/
The article provides a seasonal returns chart for Pediatrix Medical Group, Inc. (MD), showing the average monthly price return from 2016 to 2026. It includes current stock data such as the closing price and after-hours trading for November 6th. The information is presented within the Yahoo Finance platform, offering various financial tools and data.

Pediatrix Medical Group stock hits 52-week high at 30.56 USD

https://www.investing.com/news/company-news/pediatrix-medical-group-stock-hits-52week-high-at-3056-usd-93CH-4992304
Pediatrix Medical Group Inc. (MD) recently hit a new 52-week high of $30.56, reflecting positive investor sentiment and strong market performance. The company's stock has seen a 75.72% return over the past year and is considered undervalued by InvestingPro analysis despite beating Q3 2026 earnings expectations. These developments underscore the company's robust position within the healthcare sector.

Pediatrix Medical Group stock hits 52-week high at 30.56 USD

https://au.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-3056-usd-93CH-4734848
Pediatrix Medical Group (MD) stock reached a new 52-week high of $30.56, reflecting positive investor sentiment and potential growth prospects. The company also reported strong Q3 2026 financial results, exceeding Wall Street expectations with adjusted earnings of $0.72 per share on $501 million revenue, despite a cautious Q4 outlook. InvestingPro analysis suggests the stock is currently undervalued.

MD5355101 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-MD5355101/profile/
This article provides a detailed profile of the Pediatrix Medical Group, Inc. 5.375% 15-FEB-2030 RegS bond, identified as MD5355101. It covers key facts such as issuer, maturity date, face value, and minimum denomination. The profile also includes information on interest payments, coupon frequency, and a redemption schedule, offering a comprehensive overview for potential investors.

Truist Securities maintains Pediatrix Medical Group at Hold, raises price target to $31 from $28

https://www.tradingview.com/news/tradingview:4472b4e4b5698:0-truist-securities-maintains-pediatrix-medical-group-at-hold-raises-price-target-to-31-from-28/
Truist Securities has reiterated its "Hold" rating for Pediatrix Medical Group (MD) while increasing its price target from $28 to $31. This new price target suggests a potential upside of 6.2% from the stock's closing price of $29.18 on October 29. Investors can find more detailed price target data and analyst recommendations on the Forecasts tab and News Flow.
Advertisement

Press Release: Pediatrix Medical Group Reports Third Quarter Results

https://www.moomoo.com/news/post/1002801129/press-release-pediatrix-medical-group-reports-third-quarter-results
Pediatrix Medical Group reported its third-quarter 2026 results, detailing both financial performance and operational highlights for the period. The report likely includes key metrics such as revenue, net income, and earnings per share, along with commentary on factors influencing these results and future outlook.

Pediatrix Medical Group Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62698173/pediatrix-medical-group-q3-2026-earnings-call-transcript
Pediatrix Medical Group reported strong Q3 2026 results with adjusted EBITDA of $85 million, exceeding expectations due to positive same-unit revenue from both volume and pricing. The company narrowed its full-year EBITDA outlook to $290-$300 million and repurchased 3 million shares, bringing the total to 10 million since August 2025. Management highlighted strategic initiatives including telehealth expansion and exploring OB hospitals, while expressing confidence in their financial stability and ability to pursue acquisitions in the women's and children's health sector.

Pediatrix Q3 Revenue Rises 1.7% to $501.4 Million

https://grafa.com/en/news/united-states/pediatrix-medical-group-q3-2026-revenue-rises-1-7-percent
Pediatrix Medical Group (NYSE:MD) reported a 1.7% increase in third-quarter 2026 revenue, reaching $501.4 million, with net income of $47 million and adjusted earnings of $0.72 per share. This growth was driven by a combination of non-same-unit activity and same-unit revenue increases, supported by changes in payer mix, higher administrative fees, and increased patient acuity. CEO Mark S. Ordan noted that volume and pricing exceeded expectations as the company continues to focus on operating efficiency and exploring adjacent business opportunities.

Pediatrix Medical Group 3Q 2026: Revenue $501.4M, EPS $0.59— 10-Q Summary

https://www.tradingview.com/news/tradingview:fd1e00e4a2d75:0-pediatrix-medical-group-3q-2026-revenue-501-4m-eps-0-59-10-q-summary/
Pediatrix Medical Group (MD) reported its third-quarter 2026 financial results, with revenue increasing 1.7% year-over-year to $501.4 million. Despite the revenue growth, net income decreased 34.4% to $47 million, and diluted EPS fell to $0.59 from $0.84 in the prior-year quarter. The company also highlighted a 3.2% increase in nine-month revenue to $1.47 billion, with recent acquisitions contributing to growth despite declines in nine-month patient volumes.

Pediatrix Medical Group (MD) reports earnings tomorrow: what to expect

https://www.tradingview.com/news/stockstory:e8125be49094b:0-pediatrix-medical-group-md-reports-earnings-tomorrow-what-to-expect/
Pediatrix Medical Group (MD) is set to report earnings, with analysts expecting flat year-on-year revenue. The company has a history of exceeding expectations, and sentiment in the healthcare providers & services segment is positive, with MD's shares up 11.2% in the last month. Investors will be watching closely after strong prior quarter results and recent peer performance.
Advertisement

Pediatrix Medical Group stock hits 52-week high at 29.76 USD

https://www.investing.com/news/company-news/pediatrix-medical-group-stock-hits-52week-high-at-2976-usd-93CH-4972969
Pediatrix Medical Group Inc. (MD) has reached a new 52-week high of $29.76, marking a 69.44% increase over the past year and indicating strong investor confidence. The company's stock appears undervalued with a P/E ratio of 13.92 and a PEG ratio of 0.21, according to InvestingPro. This follows a strong Q2 2026 earnings beat, although Jefferies recently downgraded the stock to Hold, citing a balanced risk-reward profile after its significant rise.

Pediatrix Medical Group stock hits 52-week high at 29.76 USD

https://ng.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-2976-usd-93CH-2757693
Pediatrix Medical Group Inc. (MD) recently hit a 52-week high of $29.76, demonstrating robust growth with a 69.44% increase over the past year. The company's stock is considered undervalued by InvestingPro analysis, despite a downgrade from Jefferies to "Hold" due to its significant prior stock appreciation. Pediatrix also surpassed Wall Street's Q2 2026 earnings expectations, reporting $0.63 per share on $488 million revenue, and reaffirmed its full-year adjusted EBITDA guidance.

Pediatrix Medical Group stock hits 52-week high at 29.76 USD By Investing.com

https://in.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-2976-usd-93CH-5654556
Pediatrix Medical Group (MD) stock has reached a 52-week high of $29.76 USD, reflecting strong investor confidence and a 69.44% increase over the past year. The company's market capitalization stands at $2.35 billion, and InvestingPro analysis suggests the stock is undervalued with a P/E ratio of 13.92 and a PEG ratio of 0.21. Management's aggressive share buybacks further indicate internal confidence, while recent Q2 2026 earnings surpassed Wall Street expectations despite a slight decline in same-unit volumes.

Did Cash Flow Questions Just Shift Pediatrix Medical Group's (MD) Investment Narrative?

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/did-cash-flow-questions-just-shift-pediatrix-medical-groups
New analysis scrutinizes Pediatrix Medical Group's (MD) ability to generate cash and its declining revenue, questioning if these factors support its current valuation. Despite discounted cash flow models suggesting undervaluation, subscale operations and soft demand create a disconnect between theoretical value and market realities. The investment narrative is now heavily influenced by debates over its weakening revenue trajectory and the sustainability of its reaffirmed EBITDA range.

Pediatrix Medical Group (MD) Is Back In Focus, What Are Investors Weighing?

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/pediatrix-medical-group-md-is-back-in-focus-what-are-investo
Discussion around Pediatrix Medical Group (MD) is intensifying as its recent share price momentum raises questions about whether its valuation is fully supported by expected cash generation and revenue trends. While a DCF-based fair value suggests the stock is 11% overvalued at $26.33 compared to its current price of $29.29, traditional P/E metrics indicate it might be undervalued compared to the broader US Healthcare group. Investors are weighing the strong balance sheet and potential for buybacks against declining consolidated revenue and rising salary pressures.
Advertisement

Pediatrix Medical Group, Inc. Estimates – NYSE:MD

https://www.tradingview.com/symbols/NYSE-MD/financials-estimates/
This article provides an overview of Pediatrix Medical Group, Inc. (NYSE:MD) financials on TradingView. It directs users to explore reported financial data and analyst estimates, including income statements, balance sheets, and cash flow statements, to compare actual results with average, high, and low estimates. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.

Pediatrix Rallies Into Q3 As Fading Pricing Tailwind Meets Softer Neonatal Volumes

https://finviz.com/news/405721/pediatrix-rallies-into-q3-as-fading-pricing-tailwind-meets-softer-neonatal-volumes
Pediatrix Medical Group (MD) is heading into its third-quarter report with a significant stock rally but signs of slowing business momentum. The company faces a fading revenue-cycle collections benefit which previously boosted pricing, alongside softer neonatal volumes. The upcoming report will reveal whether improving payer mix and volume stabilization can offset these challenges and keep its full-year adjusted EBITDA outlook credible.

Pediatrix schedules October 29 results for Pediatrix Medical Group stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-schedules-october-29-results-for-pediatrix-medical-group-stock/70378259
Pediatrix Medical Group (ISIN US58502B1061) has scheduled its third-quarter results call for October 29, 2026, at 9:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2026, with the detailed release issued before US markets open. Investors will be looking for updates on revenue and earnings, following a strong second quarter where revenue reached USD 487.78 million and adjusted earnings per share hit USD 0.63.

Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026

https://www.stocktitan.net/news/MD/pediatrix-medical-group-2026-third-quarter-conference-call-webcast-w49vetjvh1qk.html
Pediatrix Medical Group (NYSE: MD) announced it will host an investor conference call and webcast on Thursday, October 29, 2026, at 9:00 a.m. ET to discuss its third-quarter 2026 operational results. A detailed press release with the results will be issued before market open on the same day. The webcast will be accessible via the company's investor relations website.

Pediatrix Medical Group, Inc. (MD) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_3300_QuantitativeReport_1791936000000
Argus raised its target price for Pediatrix Medical Group Inc. (MD) to $28.00 on October 14, 2026. The company provides physician services to hospitals and medical units, with its current price at $28.08. Related reports include analyses for DaVita Inc., Universal Health Services, Inc., Quest Diagnostics Incorporated, and HCA Healthcare, Inc.
Advertisement

Pediatrix Medical Group stock at USD 27.38, 2.25 percent below high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-at-usd-27-38-2-25-percent-below-high/70349098
Pediatrix Medical Group (MD) stock was at USD 27.38 on October 16, 2026, which is 2.25 percent below its 52-week high of USD 28.01. The company, valued at USD 2.2 billion, saw its stock decrease by 1.37 percent against the prior close. Argus recently set a price target of USD 28.00 for the stock.

Pediatrix Medical Group, Inc. (MD) Stock Price & News

https://www.syfe.com/stocks/us/md
Pediatrix Medical Group, Inc. (MD) is currently trading at US$27.48, showing a 0.65% increase today as of Oct 20, 10:14 EDT, with a market capitalization of US$2.16 billion. The stock's 52-week range has been between US$16.82 and US$28.02. Recent analyst adjustments have seen price target changes from Jefferies, UBS, and Deutsche Bank, and the company reported increased Q2 adjusted earnings and revenue.

Pediatrix Medical Group stock hits 52-week high at 28.01 USD By Investing.com

https://za.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-2801-usd-93CH-4508877
Pediatrix Medical Group (MD) stock has reached a 52-week high of $28.01, demonstrating strong investor confidence with a 71.36% one-year return. Despite a recent downgrade from Jefferies due to valuation concerns, the company reported strong Q2 2026 earnings, surpassing analyst expectations, and reaffirmed its full-year adjusted EBITDA guidance. The stock is considered undervalued by InvestingPro analysis, with potential for further upside.

Pediatrix Medical Group stock hits 52-week high at 28.01 USD

https://ng.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-2801-usd-93CH-2740702
Pediatrix Medical Group (MD) stock has reached a new 52-week high of $28.01, reflecting strong investor confidence and a 71.36% one-year return. Despite a recent downgrade from "Buy" to "Hold" by Jefferies due to valuation concerns, the company surpassed Q2 2026 earnings expectations with adjusted earnings of $0.63 per share and reaffirmed its full-year adjusted EBITDA guidance. InvestingPro analysis suggests the stock remains undervalued, highlighting its robust growth and strategic initiatives.

Pediatrix Medical Group stock hits 52-week high at 28.01 USD

https://www.investing.com/news/company-news/pediatrix-medical-group-stock-hits-52week-high-at-2801-usd-93CH-4954278
Pediatrix Medical Group Inc.'s stock reached a 52-week high of $28.01, reflecting strong investor confidence and a 71.36% one-year return. Despite positive Q2 2026 earnings that surpassed Wall Street expectations, Jefferies downgraded the stock from Buy to Hold due to valuation concerns, even though its price target was raised. The company's P/E ratio of 13.16 and PEG ratio of 0.2 suggest it remains undervalued according to InvestingPro analysis.
Advertisement

Pediatrix Medical Group stock hits 52-week high at 28.01 USD

https://in.investing.com/news/stock-market-news/pediatrix-medical-group-stock-hits-52week-high-at-2801-usd-93CH-5637526
Pediatrix Medical Group (MD) stock has reached a 52-week high of $28.01, reflecting a 71.36% one-year return and strong investor confidence. The company also reported Q2 2026 earnings that surpassed Wall Street expectations, with adjusted earnings of $0.63 per share and revenue of $488 million, though Jefferies downgraded the stock to Hold due to valuation concerns despite raising its price target. InvestingPro analysis suggests the stock remains undervalued with a low P/E ratio of 13.16 and PEG ratio of 0.2.

Pediatrix schedules November 2 results for Pediatrix Medical Group stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-schedules-november-2-results-for-pediatrix-medical-group-stock/70333578
Pediatrix Medical Group is set to report its next earnings on November 2, 2026. The company's stock is currently trading near its 52-week high at EUR 24.70, with a market capitalization of USD 2.3 billion and a P/E ratio of 13.28. The upcoming report will provide key insights into revenue growth, earnings, and patient volumes.

Pediatrix Medical Group, Inc. (MD) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3300_QuantitativeReport_1791331200000
This article provides a stock forecast for Pediatrix Medical Group, Inc. (MD), detailing an Argus report from October 7, 2026. The report includes a rating and earnings estimate for MD, which provides physician services to various medical units. It also lists related reports for other companies with updated target prices.

Pediatrix Medical Group stock weighs earnings growth against soft volumes

https://www.ad-hoc-news.de/boerse/news/corporate-news/pediatrix-medical-group-stock-weighs-earnings-growth-against-soft-volumes/70243029
Pediatrix Medical Group (MD) reported Q2 2026 adjusted EPS of USD 0.63, an increase from USD 0.53 year-over-year, despite soft patient volumes in hospital-based, office-based, and neonatal intensive care unit services. The company's adjusted earnings outpaced revenue growth, supported by a USD 42.7 million stock repurchase program. Analysts maintain a "Hold" consensus with an average target price slightly above the current trading price, indicating that continued reimbursement gains and buybacks are crucial for offsetting volume pressures.

Pediatrix Medical Group stock has November 2 results date for Pediatrix Medical Group stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-has-november-2-results-date-for-pediatrix-medical-group-stock/70209934
Pediatrix Medical Group (MD) has scheduled its next earnings report for November 2, 2026, following a second quarter that saw revenue rise 4.00% year-over-year to USD 487.78 million and adjusted EBITDA increase by 4.37% to USD 76.4 million. The company's Q2 results exceeded analyst consensus for both revenue and EPS, despite a decline in patient volume. Analysts maintain a cautious stance with an average "Hold" rating, and the stock is trading near its yearly high.
Advertisement

Pediatrix Medical Group stock has November 2 results date for Pediatrix Medical Group stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-has-november-2-results-date-for-pediatrix/70209934
Pediatrix Medical Group (MD) has announced a November 2, 2026, earnings date. The company reported a 4.00% year-over-year revenue increase to USD 487.8 million in Q2 2026, with adjusted EBITDA up 4.37% to USD 76.4 million, exceeding analyst consensus. Despite a cautious "Hold" rating from most analysts, the stock remains near its yearly high.

MD4766160 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-MD4766160/profile/
This article provides a detailed profile of the MD4766160 bond issued by Pediatrix Medical Group, Inc. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The profile also details the bond's interest payment structure, including semi-annual 6.25% coupons and a schedule of upcoming and past payouts.

Pediatrix Medical Group stock trades 8.2 percent below its 52-week high?

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-trades-8-2-percent-below-its-52-week-high/70183996
Pediatrix Medical Group (MD) stock is trading 8.2% below its 52-week high despite reporting strong Q2 2026 adjusted EPS of $0.63, beating consensus by 10.5%, and revenue growth of 4.1% to $487.8 million. This growth occurred even as patient volumes declined by 2.1%. Analysts currently hold a consensus "Hold" rating with an average 12-month price target of $26.60.

Pediatrix Medical Group stock holds as volumes stay flat

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-holds-as-volumes-stay-flat/70163616
Pediatrix Medical Group's stock was assigned a Zacks Rank of 3 (Hold) on September 22, 2026, due to an expectation of flat to slightly lower patient volumes for the full year. The company's operating performance will largely depend on these patient volumes, as they are the most concrete variable for investors to monitor. As of September 22, 2026, the stock was trading at USD 26.03 on Nasdaq, with market data indicating a target of USD 28.67 and a stop level of USD 23.46.

Pediatrix Medical Group, Inc. (MD) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/MD/
This Yahoo Finance page provides comprehensive financial information for Pediatrix Medical Group, Inc. (MD), including its stock price, historical data, performance metrics against the S&P 500, earnings trends, and analyst insights. The company, which provides newborn, maternal-fetal, and other pediatric subspecialty care, shows a current stock price of $25.86, with recent positive returns over 1-year and 3-year periods. Analyst recommendations are mixed, with an average target price of $26.33.
Advertisement

Pediatrix Medical Group (MD) Could Be 2% Below Fair Value Following Its Pullback

https://finance.yahoo.com/markets/stocks/articles/pediatrix-medical-group-md-could-101010513.html
Pediatrix Medical Group (MD) is currently trading at US$25.93, with a most followed narrative suggesting its fair value is around $26.33, indicating it is approximately 1.5% undervalued. While the stock has shown strong momentum over the past year, a recent pullback offers a fresh look at its potential upside. The company's strong balance sheet and cash position provide optionality for future growth, though risks like portfolio restructuring and higher physician compensation could impact profitability.

Pediatrix Medical Group stock trades at USD 26.16 on August 20, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pediatrix-medical-group-stock-trades-at-usd-26-16-on-august-20-2026/70138028
Pediatrix Medical Group (MD) stock closed at USD 26.16 on August 20, 2026, marking a 0.23 percent decrease. In extended hours, the stock traded slightly higher at USD 26.22, up 0.23 percent. The company is in the health care services sector and is listed on the NYSE.

Pediatrix (NYSE: MD) officer files notice for $572,619.71 stock sale

https://www.stocktitan.net/sec-filings/MD/144-pediatrix-medical-group-inc-sec-filing-ddbed43a0a11.html
Pediatrix Medical Group (NYSE: MD) officer Mary Ann E. Moore has filed a Rule 144 notice to sell 21,335 shares of common stock, valued at $572,619.71, through Merrill Lynch. These shares originate from vested stock awards, and the filing notes 81,253,271 shares outstanding as of September 11, 2026. This intended sale follows a previous sale of 9,260 shares by Moore in the last three months.

Pediatrix (NYSE: MD) officer plans $246,365 stock sale

https://www.stocktitan.net/sec-filings/MD/144-pediatrix-medical-group-inc-sec-filing-4d8f08b44ac2.html
Mary Ann E. Moore, an officer at Pediatrix Medical Group, Inc. (MD), has filed a Rule 144 notice to sell 9,260 shares of common stock through Merrill Lynch on the NYSE. The planned sale, valued at approximately $246,365.53, is scheduled for August 14, 2026. The shares to be sold were acquired through the vesting of stock awards over several years.

Pediatrix Medical Group (MD) Faces Demand Questions, Is The Recent Rally Already Priced In?

https://www.sahmcapital.com/news/content/pediatrix-medical-group-md-faces-demand-questions-is-the-recent-rally-already-priced-in-2026-08-22
Pediatrix Medical Group (MD) is facing questions regarding demand for its services due to declining revenue and limited sales growth, despite a significant stock rally of 24.8% year-to-date. While a common narrative suggests the stock is slightly overvalued at $26.33 compared to its current price of $26.57, a Discounted Cash Flow (DCF) model implies it is heavily undervalued with an estimated future cash flow value of $58.51. The article advises investors to review the differing valuations and consider their own assumptions.
Advertisement

Jefferies downgrades Pediatrix Medical stock rating on valuation

https://www.investing.com/news/analyst-ratings/jefferies-downgrades-pediatrix-medical-stock-rating-on-valuation-93CH-4866588
Jefferies has downgraded Pediatrix Medical Group (NYSE: MD) from Buy to Hold, citing valuation concerns after the stock surged 150% in two years, including a 61% return in the last year. Despite management's strong execution, the firm believes the risk-reward is now neutral, anticipating headwinds from the Affordable Care Act's premium tax credit that could cap near-term earnings growth. While the stock's re-rating places it at its long-term average EV/EBITDA, InvestingPro analysis still suggests it is undervalued relative to its Fair Value.

ETFs Investing in Pediatrix Medical Group, Inc. Stocks

https://www.tradingview.com/symbols/BIVA-MD/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Pediatrix Medical Group, Inc. (MD). The funds are sorted by market value and include details such as issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The compilation aims to provide investors with accessible and diversified opportunities with lower risk.

PEDIATRIX MEDICAL GROUP INC : JEFFERIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $28 FROM $27

https://www.bitget.com/amp/news/detail/12560605698885
Jefferies has downgraded Pediatrix Medical Group Inc. (MD.N) from a "Buy" rating to a "Hold" rating. Despite the downgrade, the firm increased its target price for the company from $27 to $28. This adjustment reflects a revised outlook from Jefferies regarding the medical group.

Will Earnings Beat and Major Buybacks Change Pediatrix Medical Group's (MD) Narrative

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/will-earnings-beat-and-major-buybacks-change-pediatrix-medic
Pediatrix Medical Group (MD) recently reported strong Q2 2026 results with increased sales and net income, alongside significant share repurchases. These actions support per-share metrics amidst ongoing challenges like reimbursement risk and physician cost inflation. While the company projects revenue growth and a fair value of $23.17, indicating a 13% downside, investors should consider varying analyst expectations and the impact of these financial moves on the company's long-term investment narrative.

Will Earnings Beat and Major Buybacks Change Pediatrix Medical Group's (MD) Narrative

https://simplywall.st/stocks/us/healthcare/nyse-md/pediatrix-medical-group/news/will-earnings-beat-and-major-buybacks-change-pediatrix-medic/amp
Pediatrix Medical Group (MD) recently reported strong Q2 2026 results, with increased sales and net income, alongside significant share repurchases. These actions, particularly the buybacks, are supporting the company's per-share metrics amidst ongoing challenges like reimbursement and labor costs. The article suggests that while these positive developments are notable, investors should remain aware of potential sustained reimbursement pressures and explore various analyst perspectives.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement